Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: Results of sequential cancer and leukemia group B studies

Journal of Clinical Oncology

Volumn 31, Issue 4, 2013, Pages 440-447

  Woyach, Jennifer A ^a   Ruppert, Amy S ^a   Rai, Kanti ^b   Lin, Thomas S ^d   Geyer, Susan ^a   Kolitz, Jonathan ^b   Appelbaum, Frederick R ^e   Tallman, Martin S ^c   Belch, Andrew R ^f   Morrison, Vicki A ^g   Larson, Richard A ^h   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b North Shore Long Island Jewish Medical System   (United Kingdom)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

^e USA   (United States)

^f CROSS CANCER INSTITUTE   (Canada)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; FLUDARABINE; FLUDARABINE PLUS RITUXIMAB; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONFIDENCE INTERVAL; FEMALE; GROUPS BY AGE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; AGE; AGING; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DISEASE FREE SURVIVAL; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIDARABINE;

MLCS; MLOWN;

EID: 84874773634     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.5646     Document Type: Article

References (19)

1. Diehl LF, Karnell LH, Menck HR: The American College of Surgeons Commission on Cancer and the American Cancer Society: The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 86: 2684-2692, 1999 (Pubitemid 30004673)
2. Ries LA, Melbert D, Krapcho M, et al: SEER Clinical Statistics Review, 1975-2005. Bethesda, MD, National Cancer Institute, 2008
3. Thurmes P, Call T, Slager S, et al: Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 49: 49-56, 2008 (Pubitemid 351146882)
4. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343: 1750-1757, 2000
5. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370: 230-239, 2007 (Pubitemid 47069536)
6. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25: 793-798, 2007 (Pubitemid 350002879)
7. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101: 6-14, 2003 (Pubitemid 36025880)
8. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376: 1164-1174, 2010
9. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23: 4079-4088, 2005 (Pubitemid 46211313)
10. Eichhorst BF, Busch R, Stilgenbauer S, et al: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114: 3382-3391, 2009
11. Ferrajoli A, O'Brien S, Wierda W, et al: Treatment of patients with CLL 70 years old and older: A single center experience of 142 patients. Leuk Lymphoma 46:48, 2005
12. Hillmen P, Gribben JG, Follows GA, et al: Rituximab plus chlorambucil in patients with CD20- positive B-cell chronic lymphocytic leukemia (CLL): Final response analysis of an open-label phase II study. Blood 116:697, 2010 (abstr 697)
13. Foa R, Ciolli S, Di Raimondo F, et al: A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the first interim analysis. Blood 116:2462, 2010 (abstr 2462)
14. Byrd JC, Peterson BL, Rai KR, et al: Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: Final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma 50: 1589-1596, 2009
15. Lin TS, Donohue KA, Byrd JC, et al: Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: Final analysis of CALGB 10101. J Clin Oncol 28: 4500-4506, 2010
16. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87: 4990-4997, 1996 (Pubitemid 26189840)
17. Stevens LA, Li S, Wang C, et al: Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 55:S23-S33, 2010 (suppl 2)
18. Robertson LE, O'Brien S, Kantarjian H, et al: A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 9:1444- 1449, 1995
19. Martell RE, Peterson BL, Cohen HJ, et al: Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: A CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol 50: 37-45, 2002 (Pubitemid 34743994)